The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Mouse Models of Alzheimer’s Disease
Open accessAbstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss and personality changes, eventually leading to dementia. The pathological hallmarks of AD are senile plaques and neurofibrillary tangles, which comprise abnormally aggregated β-amyloid peptide (Aβ) and hyperphosphorylated tau protein. To develop preventive, diagnostic, and therapeutic strategies for AD, it is essential to establish animal models that recapitulate the pathophysiological process of AD. In this review, we will summarize the advantages and limitations of various mouse models of AD, including transgenic, knock-in, and injection models based on Aβ and tau. We will also discuss other mouse models based on neuroinflammation because recent genetic studies have suggested that microglia are crucial in the pathogenesis of AD. Although each mouse model has its advantages and disadvantages, further research on AD pathobiology will lead to the establishment of more accurate mouse models, and accelerate the development of innovative therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Modeling these pathological hallmarks has largely relied on transgenic cellular and animal models harboring genetic mutations linked to ADAD (3–5).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“5xFAD Mice This mouse model was generated by coexpressing the following five FAD mutations in APP/PS1 double-transgenic mice: the Swedish (KM670/671NL), Florida (I716V), and London (V717I) mutations in the APP gene, and the M146L (A > C) and L286V mutations in the PSEN1 gene, causing the accelerated formation of Aβ pl…”
MethodPhases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,780
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Self-citationJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,506
Kosik, K. S., Joachim, C. L., & Selkoe, D. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.4044 · Cited by 1,491
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Pérez‐Tur, J., Hutton, M., Buée, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,486
Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Single App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Zhou, Y., Song, W. M., Andhey, P. S., Swain, A., Levy, T., Miller, K. R., Poliani, P. L., Cominelli, M., Grover, S., Gilfillan, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0695-9 · Cited by 1,150
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053
Chishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955
The role of presenilin cofactors in the γ-secretase complex
Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M., Takahashi, Y., Thinakaran, G., & Iwatsubo, T. (2003) · Nature · doi:10.1038/nature01506 · Cited by 887
Self-citationYuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817
Tau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
TREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease
Wesseling, H., Mair, W., Kumar, M., Schlaffner, C. N., Tang, S., Beerepoot, P., Fatou, B., Guise, A. J., Cheng, L., Takeda, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.029 · Cited by 688
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685
He, Z., Guo, J. L., McBride, J. D., Narasimhan, S., Kim, H., Changolkar, L., Zhang, B., Gathagan, R. J., Yue, C., Dengler, C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4443 · Cited by 645
Microglial response to amyloid plaques in APPsw transgenic mice.
Frautschy, S. A., Yang, F., Irrizarry, M., Hyman, B. T., Saido, T. C., Hsiao, K., & Cole, G. M. (1998) · Europe PMC (PubMed Central) · Cited by 592
Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587
Randomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545
DeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516
Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits
Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., Shirakawa, K., Minami, S. S., Defensor, E., Mok, S. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3951 · Cited by 516
Ahmed, Z., Cooper, J., Murray, T. K., Garn, K., McNaughton, E., Clarke, H., Parhizkar, S., Ward, M. A., Cavallini, A., Jackson, S., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1254-6 · Cited by 484
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15436-0 · Cited by 450
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · cited 1×
“Gantenerumab bound to cerebral Aβ and enhanced the removal of small Aβ plaques by recruiting microglia, and prevented new plaque formation in PS2APP mice (Bohrmann et al., 2012).”
BackgroundA Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442
Kennedy, M. E., Stamford, A. W., Chen, X., Cox, K., Cumming, J. N., Dockendorf, M. F., Egan, M. F., Ereshefsky, L., Hodgson, R. A., Hyde, L. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 441
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200861 · Cited by 437
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434
Tomita, T., Maruyama, K., Saido, T. C., Kume, H., Shinozaki, K., Tokuhiro, S., Capell, A., Walter, J., Grünberg, J., Haass, C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2025 · Cited by 385
Self-citationPassive Immunization with Anti-Tau Antibodies in Two Transgenic Models
Chai, X., Wu, S., Murray, T. K., Kinley, R. D., Cella, C. V., Sims, H., Buckner, N., Hanmer, J. M., Davies, P., O’Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 363
Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340
One of the Antigenic Determinants of Paired Helical Filaments Is Related to Tau Protein1
Nukina, N., & Ihara, Y. (1986) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a135625 · Cited by 338
TREM2 function impedes tau seeding in neuritic plaques
Leyns, C. E. G., Gratuze, M., Narasimhan, S., Jain, N., Koscal, L. J., Jiang, H., Manis, M., Colonna, M., Lee, V. M. Y., Ulrich, J. D., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0433-0 · Cited by 332
Wright, A. L., Zinn, R., Hohensinn, B., Konen, L. M., Beynon, S. B., Tan, R. P., Clark, I. A., Abdipranoto, A., & Vissel, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059586 · Cited by 322
Kamphuis, W., Mamber, C., Moeton, M., Kooijman, L., Sluijs, J. A., Jansen, A. H. P., Verveer, M., de Groot, L. R., Smith, V. D., Rangarajan, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042823 · Cited by 320
Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
Arai, H., Terajima, M., Miura, M., Higuchi, S., Muramatsu, T., Machida, N., Seiki, H., Takase, S., Clark, C., Lee, V. M., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380414 · Cited by 314
Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.
Solomon, B., Koppel, R., Hanan, E., & Katzav-Gozansky, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.452 · Cited by 314
Wilcock, D. M., Rojiani, A. M., Rosenthal, A., Levkowitz, G., Subbarao, S., Alamed, J., Wilson, D. H., Wilson, N., Freeman, M. J., Gordon, M. N., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1090-04.2004 · Cited by 302
Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition
Dam, D. V., D’Hooge, R., Staufenbiel, M., Ginneken, C. J. V., Meir, F. V., & Deyn, P. P. D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02444.x · Cited by 300
The Profile of Soluble Amyloid β Protein in Cultured Cell Media
Wang, R., Sweeney, D. A., Gandy, S., & Sisodia, S. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.31894 · Cited by 293
Tucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140741 · Cited by 272 · cited 1×
“The administration of mAb158 to aged Tg-ArcSwe mice reduced Aβ protofibrils without changing insoluble Aβ levels (Tucker et al., 2015).”
BackgroundLord, A., Kalimo, H., Eckman, C., Zhang, X.-Q., Lannfelt, L., & Nilsson, L. N. G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.12.007 · Cited by 260
Saito, T., Mihira, N., Matsuba, Y., Sasaguri, H., Hashimoto, S., Narasimhan, S., Zhang, B., Murayama, S., Higuchi, M., Lee, V. M. Y., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009487 · Cited by 248
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., Shiovitz, T., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0607 · Cited by 240
Lemere, C. A., Beierschmitt, A., Iglesias, M., Spooner, E. T., Bloom, J. K., Leverone, J. F., Zheng, J. B., Seabrook, T. J., Louard, D., Li, D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63296-8 · Cited by 230
Maia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., & Jucker, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006446 · Cited by 204
Richards, J. G., Higgins, G. A., Ouagazzal, A., Ozmen, L., Kew, J. N. C., Bohrmann, B., Malherbe, P., Brockhaus, M., Loetscher, H., Czech, C., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08989.2003 · Cited by 204
Mitani, Y., Yarimizu, J., Saita, K., Uchino, H., Akashiba, H., Shitaka, Y., Ni, K., & Matsuoka, N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4264-11.2012 · Cited by 203
Britschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904866106 · Cited by 201
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809316 · Cited by 177 · cited 1×
“Various BACE1 inhibitors, such as verubecestat, umibecestat, and atabecestat have been developed, and their efficacy and pharmacodynamics have been investigated in animal models (Kennedy et al., 2016; Neumann et al., 2018; Koriyama et al., 2021).”
BackgroundFactors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice
Gamache, J., Benzow, K. A., Forster, C. L., Kemper, L. J., Hlynialuk, C. J. W., Furrow, E., Ashe, K. H., & Koob, M. D. (2019) · Nature Communications · doi:10.1038/s41467-019-10428-1 · Cited by 174
Lalonde, R., Kim, H. D., Maxwell, J. A., & Fukuchi, K. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.08.028 · Cited by 170
Jackson, S. J., Kerridge, C., Cooper, J., Cavallini, A., Falcon, B., Cella, C. V., Landi, A., Szekeres, P. G., Murray, T. K., Ahmed, Z., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3542-15.2016 · Cited by 163
Lord, A., Gumucio, A., Englund, H., Sehlin, D., Sundquist, V. S., Söderberg, L., Möller, C., Gellerfors, P., Lannfelt, L., Pettersson, F. E., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.08.007 · Cited by 158
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
McDade, E., Voytyuk, I., Aisen, P. S. S., Bateman, R. J., Carrillo, M. C., Strooper, B. D., Haass, C., Reiman, E. M., Sperling, R. A., Tariot, P. N., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00545-1 · Cited by 151
Inflammation occurs early during the Aβ deposition process in TgCRND8 mice
Dudal, S., Krzywkowski, P., Paquette, J., Morissette, C., Lacombe, D., Tremblay, P., & Gervais, F. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.008 · Cited by 138
Novel plasma biomarker surrogating cerebral amyloid deposition
KANEKO, N., Nakamura, A., Washimi, Y., Kato, T., Sakurai, T., Arahata, Y., Bundo, M., Takeda, A., Niida, S., Ito, K., et al. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.353 · Cited by 138
Switchable photooxygenation catalysts that sense higher-order amyloid structures
Taniguchi, A., Shimizu, Y., Oisaki, K., Sohma, Y., & Kanai, M. (2016) · Nature Chemistry · doi:10.1038/nchem.2550 · Cited by 129
Involvement of in the abnormal hyperphosphorylation of tau and its reversal by Memantine
Chohan, M. O., Khatoon, S., Iqbal, I.-G., & Iqbal, K. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.06.021 · Cited by 124
Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., Terasaki, T., Hashimoto, T., & Iwatsubo, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2021-09.2009 · Cited by 117
Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains
Moore, B. D., Chakrabarty, P., Levites, Y., Kukar, T. L., Baine, A.-M. T., Moroni, T., Ladd, T. B., Das, P., Dickson, D. W., & Golde, T. E. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt121 · Cited by 115
Ayalon, G., Lee, S.-H., Adolfsson, O., Foo‐Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H. S., Bravo, J., Brendza, R. P., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 112
Novak, G., Streffer, J. R., Timmers, M., Henley, D. B., Brashear, H. R., Bogert, J., Russu, A., Janssens, L., Tesseur, I. C., Tritsmans, L., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00614-5 · Cited by 108
Glenner, G. G. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.08.020 · Cited by 104
Aging in the Canine and Feline Brain
Vite, C. H., & Head, E. (2014) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2014.07.008 · Cited by 103
Near-Infrared Photoactivatable Oxygenation Catalysts of Amyloid Peptide
Ni, J., Taniguchi, A., Ozawa, S., Hori, Y., Kuninobu, Y., Saito, T., Saido, T. C., Tomita, T., Sohma, Y., & Kanai, M. (2018) · Chem · doi:10.1016/j.chempr.2018.02.008 · Cited by 101
Self-citationUhlmann, R. E., Rother, C., Rasmussen, J., Schelle, J., Bergmann, C., Ullrich Gavilanes, E. M., Fritschi, S. K., Buehler, A., Baumann, F., Skodras, A., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-00737-w · Cited by 87
Extracellular Tau and Its Potential Role in the Propagation of Tau Pathology
Yamada, K. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00667 · Cited by 86
REVIEW: γ‐Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State
Panza, F., Frisardi, V., Imbimbo, B. P., Capurso, C. A., Logroscino, G., Sancarlo, D., Seripa, D., Vendemiale, G., Pilotto, A., & Solfrizzi, V. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00164.x · Cited by 80
Chhatwal, J. P., Schultz, S. A., McDade, E., Schultz, A. P., Liu, L., Hanseeuw, B. J., Joseph‐Mathurin, N., Feldman, R. L., Fitzpatrick, C. D., Sparks, K. P., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00375-6 · Cited by 76
Catalytic photooxygenation degrades brain Aβ in vivo
Nagashima, N., Ozawa, S., Furuta, M., Oi, M., Hori, Y., Tomita, T., Sohma, Y., & Kanai, M. (2021) · Science Advances · doi:10.1126/sciadv.abc9750 · Cited by 76
Self-citationRoertgen, K. E., Parisi, J. E., Clark, H. B., Barnes, D. L., O’Brien, T. D., & Johnson, K. H. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02069-1 · Cited by 67
Characterization of tau binding by gosuranemab
Sopko, R., Golonzhka, O., Arndt, J. W., Quan, C., Czerkowicz, J., Cameron, A., Smith, B., Yogapriya, M., Gibbons, G. S., Kim, S., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105120 · Cited by 65
Koriyama, Y., Hori, A., Ito, H., Yonezawa, S., Baba, Y., Tánimoto, N., Ueno, T., Yamamoto, S., Yamamoto, T., Asada, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01917 · Cited by 59
Photo-oxygenation by a biocompatible catalyst reduces amyloid-β levels in Alzheimer’s disease mice
Ozawa, S., Hori, Y., Shimizu, Y., Taniguchi, A., Suzuki, T., Wang, W., Chiu, Y. W., Koike, R., Yokoshima, S., Fukuyama, T., et al. (2021) · Brain · doi:10.1093/brain/awab058 · Cited by 58
Self-citationNakamura, S., Tamaoka, A., Sawamura, N., Shoji, S., Nakayama, H., Ono, F., Sakakibara, I., Yoshikawa, Y., Mori, H., Naoaki, G. O. T. O., et al. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12160-9 · Cited by 42
Pharmacological relevance of CDK inhibitors in Alzheimer's disease
Malhotra, N., Gupta, R. V., & Kumar, P. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105115 · Cited by 42
Photo-oxygenation inhibits tau amyloid formation
Suzuki, T., Hori, Y., Sawazaki, T., Shimizu, Y., Nemoto, Y., Taniguchi, A., Ozawa, S., Sohma, Y., Kanai, M., & Tomita, T. (2019) · Chemical Communications · doi:10.1039/c9cc01728c · Cited by 39
Self-citationAlzheimer’s Aβ vaccination of rhesus monkeys (Macaca mulatta)
Gandy, S., DeMattos, R. B., Lemere, C. A., Heppner, F. L., Leverone, J. F., Aguzzi, A., Ershler, W. B., Dai, J., Fraser, P., George‐Hyslop, P. S., et al. (2003) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2003.12.002 · Cited by 35
Dysregulated Metabolism of the Amyloid‐β Protein and Therapeutic Approaches in Alzheimer Disease
Kikuchi, K., Kidana, K., Tatebe, T., & Tomita, T. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26129 · Cited by 34
Self-citationHosokawa, M., Masuda‐Suzukake, M., Shitara, H., Shimozawa, A., Suzuki, G., Kondo, H., Nonaka, T., Campbell, W. D., Arai, T., & Hasegawa, M. (2021) · Brain · doi:10.1093/brain/awab289 · Cited by 30
Nies, S. H., Takahashi, H., Herber, C. S., Huttner, A. J., Chase, A., & Strittmatter, S. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101159 · Cited by 25
Photo-Oxygenation: An Innovative New Therapeutic Approach Against Amyloidoses
Ikeda, T., Hori, Y., Sohma, Y., Kanai, M., & Tomita, T. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-78787-5_52 · Cited by 3
Self-citation
Cited by
Sorted by citations
Mitochondria in health, disease, and aging
Harrington, J. S., Ryter, S. W., Plataki, M. E., Price, D. R., & Choi, A. M. K. (2023) · Physiological Reviews · doi:10.1152/physrev.00058.2021 · Cited by 641
Magnetic iron oxide nanoparticles for brain imaging and drug delivery
Qiao, R., Fu, C., Forgham, H., Javed, I., Huang, X., Zhu, J., Whittaker, A. K., & Davis, T. P. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114822 · Cited by 257
Is Alzheimer disease a disease?
Korczyn, A. D., & Grinberg, L. T. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00940-4 · Cited by 198
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
Therapeutic inhibition of ferroptosis in neurodegenerative disease
Ryan, S. K., Ugalde, C. L., Rolland, A., Skidmore, J., Devos, D., & Hammond, T. R. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.07.007 · Cited by 127
Metadata
- Authors
- Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T.
- Affiliations
- The University of Tokyo (JP)
- Corresponding author
- Tomita, Taisuke
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2022-06-21
- Volume
- 15
- Pages
- 912995-912995
- ISSN
- 1662-5099 (ISSN-L)
- PMC
- PMC9254908
- OpenAlex
- W4283267746
- Cited by
- 213
- References
- 128
- Citations by year
- 2026: 40 · 2025: 63 · 2024: 77 · 2023: 31 · 2022: 1
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Molecular Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Moonshot Research and Development Program
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, mouse model, transgenic mice, knock-in mice, amyloid-beta, tau protein, neurofibrillary tangles, amyloid plaques, neuroinflammation, microglia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review